Skip to Content

    Boston-based drugmaker Vertex, which specializes in rare disorders like cystic fibrosis, doesn’t always attract Big Pharma–level attention. But the firm is on a serious growth trajectory, slated for double-digit expansion in the coming years, per analysts. And the company is branching out into new, brand-name science it hopes can add to its $43 billion market value, including a recent $950 million deal to acquire Semma Therapeutics—a startup that aims to use stem cells to cure Type 1 diabetes.

    Subscribe to Fortune’s Brainstorm Health Daily newsletter, where we monitor advances in healthcare and biopharma.

    Company Information

    Overall Score2.6
    Sector
    Health Care
    Industry
    Biotechnology
    CEO
    Jeffrey Leiden
    Websitehttps://www.vrtx.com
    HQ Location
    Boston
    Country
    U.S.
    Revenues ($M) (Past 12 Months)$3,454
    Profits ($M) (Past 12 Months)$2,215
    Market Value as of Oct. 9, 2019 ($M)$43,370
    Employees2,500
    Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

    Refinitiv Sustainable Leadership Monitor

    placeholder